Zebrafish: an emerging technology for in vivo pharmacological assessment to identify potential safety liabilities in early drug discovery

被引:205
作者
Barros, T. P. [1 ]
Alderton, W. K.
Reynolds, H. M. [1 ]
Roach, A. G.
Berghmans, S.
机构
[1] Summit Cambridge Ltd, Cambridge, England
关键词
zebrafish; safety pharmacology; liability; high throughput; model organism;
D O I
10.1038/bjp.2008.249
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The zebrafish is a well-established model organism used in developmental biology. In the last decade, this technology has been extended to the generation of high-value knowledge on safety risks of novel drugs. Indeed, the larval zebrafish appear to combine advantages of whole organism phenotypic assays and those (rapid production of results with minimal resource engagement) of in vitro high-throughput screening techniques. Thus, if appropriately evaluated, it can offer undeniable advantages in drug discovery for identification of target and off-target effects. Here, we review some applications of zebrafish to identify potential safety liabilities, particularly before lead/candidate selection. For instance, zebrafish cardiovascular system can be used to reveal decreases in heart rate and atrial-ventricular dissociation, which may signal human ether-a-go-go-related gene (hERG) channel blockade. Another main area of interest is the CNS, where zebrafish behavioural assays have been and are further being developed into screening platforms for assessment of locomotor activity, convulsant and proconvulsant liability, cognitive impairment, drug dependence potential and impaired visual and auditory functions. Zebrafish also offer interesting possibilities for evaluating effects on bone density and gastrointestinal function. Furthermore, available knowledge of the renal system in larval zebrafish can allow identification of potential safety issues of drug candidates on this often neglected area in early development platforms. Although additional validation is certainly needed, the zebrafish is emerging as a versatile in vivo animal model to identify off-target effects that need investigation and further clarification early in the drug discovery process to reduce the current, high degree of attrition in development.
引用
收藏
页码:1400 / 1413
页数:14
相关论文
共 132 条
[91]   Atrioventricular block in a newborn with acquired long QT syndrome [J].
Phillips, JR ;
Case, CL ;
Gillette, PC .
CARDIOLOGY IN THE YOUNG, 2001, 11 (06) :680-682
[92]   Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients [J].
Pirmohamed, M ;
James, S ;
Meakin, S ;
Green, C ;
Scott, AK ;
Walley, TJ ;
Farrar, K ;
Park, BK ;
Breckenridge, AM .
BMJ-BRITISH MEDICAL JOURNAL, 2004, 329 (7456) :15-19
[93]   New perspectives in CNS safety pharmacology [J].
Porsolt, RD ;
Lemaire, M ;
Dürmüller, N ;
Roux, S .
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2002, 16 (03) :197-207
[94]   Zebrafish comparative genomics and the origins of vertebrate chromosomes [J].
Postlethwait, JH ;
Woods, IG ;
Ngo-Hazelett, P ;
Yan, YL ;
Kelly, PD ;
Chu, F ;
Huang, H ;
Hill-Force, A ;
Talbot, WS .
GENOME RESEARCH, 2000, 10 (12) :1890-1902
[95]   In vivo imaging and genetic analysis link bacterial motility and symbiosis in the zebrafish gut [J].
Rawls, John F. ;
Mahowald, Michael A. ;
Goodman, Andrew L. ;
Trent, Chad M. ;
Gordon, Jeffrey I. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (18) :7622-7627
[96]   Kit-like immunoreactivity in the zebrafish gastrointestinal tract reveals putative ICC [J].
Rich, A. ;
Leddon, S. A. ;
Hess, S. L. ;
Gibbons, S. J. ;
Miller, S. ;
Xu, X. ;
Farrugai, G. .
DEVELOPMENTAL DYNAMICS, 2007, 236 (03) :903-911
[97]  
RICHARDS FM, 2006, INVEST OPHTH VIS SCI, V47, P123
[98]   Connections of the ventral telencephalon (subpallium) in the zebrafish (Danio rerio) [J].
Rink, E ;
Wullimann, MF .
BRAIN RESEARCH, 2004, 1011 (02) :206-220
[99]  
Rombough P, 2002, J EXP BIOL, V205, P1787
[100]   Zebrafish assays for drug toxicity screening [J].
Rubinstein, Amy L. .
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2006, 2 (02) :231-240